Genomic and non-genomic interactions of PPARα with xenobiotic-metabolizing enzymes

Trends in Endocrinology and Metabolism

Volumn 15, Issue 7, 2004, Pages 324-330

  Barbier, Olivier ^a   Fontaine, Coralie ^a   Fruchart, Jean Charles ^a   Staels, Bart ^a  

^a INSTITUT PASTEUR DE LILLE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL] BENZAMIDE; 5 (2,4 DIOXO 5 THIAZOLIDINYLMETHYL) 2 METHOXY N [4 (TRIFLUOROMETHYL)BENZYL]BENZAMIDE; BEZAFIBRATE; BILE ACID; CERIVASTATIN; CLOFIBRATE; CYTOCHROME P450; FENOFIBRATE; FIBRIC ACID DERIVATIVE; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR AGONIST; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PIOGLITAZONE; PREGNANE X RECEPTOR; RAGAGLITAZAR; ROSIGLITAZONE; SIMVASTATIN; TESAGLITAZAR; TROGLITAZONE; UNCLASSIFIED DRUG; XENOBIOTIC AGENT;

DNA MICROARRAY; DYSLIPIDEMIA; GENE EXPRESSION; GENE INTERACTION; GENETIC TRANSCRIPTION; GENOME; HOMEOSTASIS; HUMAN; HYDROXYLATION; ISCHEMIC HEART DISEASE; METABOLIC DISORDER; MUSCLE DISEASE; MYALGIA; MYOPATHY; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; RHABDOMYOLYSIS; XENOBIOTIC METABOLISM;

ANIMALS; ENZYMES; GENOMICS; HUMANS; PPAR ALPHA; XENOBIOTICS;

EID: 4444344438     PISSN: 10432760     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tem.2004.07.007     Document Type: Review

References (74)

1. O. Barbier Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis Arterioscler. Thromb. Vasc. Biol. 22 2002 717 726
2. G.J. Etgen, and N. Mantlo PPAR ligands for metabolic disorders Curr. Top. Med. Chem. 3 2003 1649 1661
3. V. Bocher PPARs: transcription factors controlling lipid and lipoprotein metabolism Ann. New York Acad. Sci. 967 2002 7 18
4. G. Chinetti Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation Inflamm. Res. 49 2000 497 505
5. X.Y. Yang Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor γ (PPARγ) agonists. PPARγ co-association with transcription factor NFAT J. Biol. Chem. 275 2000 4541 4544
6. P. Gervois Negative regulation of human fibrinogen gene expression by peroxisome proliferator-activated receptor α agonists via inhibition of CCAAT box/enhancer-binding protein β J. Biol. Chem. 276 2001 33471 33477
7. M. Fu Peroxisome proliferator-activated receptor γ inhibits transforming growth factor β-induced connective tissue growth factor expression in human aortic smooth muscle cells by interfering with Smad3 J. Biol. Chem. 276 2001 45888 45894
8. T.M. Willson The PPARs: from orphan receptors to drug discovery J. Med. Chem. 43 2000 527 550
9. P. Delerive Oxidized phospholipids activate PPARα in a phospholipase A2-dependent manner FEBS Lett. 471 2000 34 38
10. S.S. Davies Oxidized alkyl phospholipids are specific, high affinity peroxisome proliferator-activated receptor γ ligands and agonists J. Biol. Chem. 276 2001 16015 16023
11. F.M. Martens Metabolic and additional vascular effects of thiazolidinediones Drugs 62 2002 1463 1480
12. P.J. Brown Identification of a subtype selective human PPARα agonist through parallel-array synthesis Bioorg. Med. Chem. Lett. 11 2001 1225 1227
13. K.K. Brown A novel N-aryl tyrosine activator of peroxisome proliferator-activated receptor-γ reverses the diabetic phenotype of the Zucker diabetic fatty rat Diabetes 48 1999 1415 1424
14. W.R. Oliver Jr A selective peroxisome proliferator-activated receptor delta agonist promotes reverse cholesterol transport Proc. Natl. Acad. Sci. U. S. A. 98 2001 5306 5311
15. F. Charatan Bayer decides to withdraw cholesterol lowering drug Br. Med. J. 323 2001 359
16. W.K. Bock Vertebrate UDP-glucuronosyltransferases: functional and evolutionary aspects Biochem. Pharmacol. 66 2003 691 696
17. P. Honkakoski, and M. Negishi Regulation of cytochrome P450 (CYP) genes by nuclear receptors Biochem. J. 347 2000 321 337
18. T.H. Rushmore, and T. Kong Pharmacogenomics, regulation and signalling pathways of phase I and II drug metabolizing enzymes Curr. Drug Metab. 3 2002 481 490
19. E.F. Johnson Regulation of P450 4A expression by peroxisome proliferator activated receptors Toxicology 181/182 2002 203 206
20. D.R. Nelson Cytochrome P450 and the individuality of species Arch. Biochem. Biophys. 369 1999 1 10
21. C.D. King UDP-glucuronosyltransferases Curr. Drug Metab. 1 2000 143 161
22. C. Guillemette Pharmacogenomics of human UDP-glucuronosyltransferase enzymes Pharmacogenomics J. 3 2003 136 158
23. T.M. Willson, and S.A. Kliewer PXR, CAR and drug metabolism Nat. Rev. Drug Discov. 1 2002 259 266
24. H. Honeck Cytochrome P450-dependent renal arachidonic acid metabolism in deoxycorticosterone acetate-salt hypertensive mice Hypertension 36 2000 610 616
25. L.A. Cowart The CYP4A isoforms hydroxylate epoxyeicosatrienoic acids to form high affinity ligands J. Biol. Chem. 277 2002 35105 35112
26. S.S. Lee Targeted disruption of the α isoform of the peroxisome proliferator-activated receptor gene in mice results in abolishment of the pleiotropic effects of peroxisome proliferators Mol. Cell. Biol. 15 1995 3012 3022
27. R.C. Cattley Do peroxisome proliferating compounds pose a hepatocarcinogenesis hazard to humans? Regul. Toxicol. Pharmacol. 27 1998 47 60
28. L. Richert Effects of clofibric acid on mRNA expression profiles in primary cultures of rat, mouse and human hepatocytes Toxicol. Appl. Pharmacol. 191 2003 130 146
29. J. Fiedler Effect of peroxisome proliferator-activated receptor α activation on leukotriene B4 metabolism in isolated rat hepatocytes J. Pharmacol. Exp. Ther. 299 2001 691 697
30. O. Barbier The UDP-glucuronosyltransferase 1A9 enzyme is a peroxisome proliferator-activated receptor α and γ target gene J. Biol. Chem. 278 2003 13975 13983
31. D. Turgeon Glucuronidation of arachidonic and linoleic acid metabolites by human UDP-glucuronosyltransferases J. Lipid Res. 44 2003 1182 1191
32. K.A. Berry Urinary metabolites of leukotriene B4 in the human subject J. Biol. Chem. 278 2003 24449 24460
33. I. Pineda Torra Characterization of the human PPARα promoter: identification of a functional nuclear receptor response element Mol. Endocrinol. 16 2002 1013 1028
34. F. Gonzalez The peroxisome proliferator-activated receptor α (PPARα): role in hepatocarcinogenesis Mol. Cell. Endocrinol. 193 2002 71 79
35. Y. Watanabe Troglitazone glucuronidation in human liver and intestine microsomes: high catalytic activity of UGT1A8 and UGT1A10 Drug Metab. Dispos. 30 2002 1462 1469
36. T. Prueksaritanont Effects of fibrates on metabolism of statins in human hepatocytes Drug Metab. Dispos. 30 2002 1280 1287
37. T. Prueksaritanont Mechanistic studies on metabolic interactions between gemfibrozil and statins J. Pharmacol. Exp. Ther. 301 2002 1042 1051
38. Y. Yoshigae Characterization of UDP-glucuronosyltransferases (UGTs) involved in the metabolism of troglitazone in rats and humans J. Toxicol. Sci. 25 2000 433 441
39. M.A. Khan A prospective, randomized comparison of the metabolic effects of pioglitazone or rosiglitazone in patients with type 2 diabetes who were previously treated with troglitazone Diabetes Care 25 2002 708 711
40. B.B. Lohray (-)3-[4-[2-(Phenoxazin-10-yl)ethoxy]phenyl]-2-ethoxypropanoic acid [(-)DRF 2725]: a dual PPAR agonist with potent antihyperglycemic and lipid modulating activity J. Med. Chem. 44 2001 2675 2678
41. T. Davis Tesaglitazar AstraZeneca IDrugs 5 2002 924 926
42. K. Murakami A novel insulin sensitizer acts as a coligand for peroxisome proliferator-activated receptor-α (PPAR-α) and PPAR-γ: effect of PPAR-α activation on abnormal lipid metabolism in liver of Zucker fatty rats Diabetes 47 1998 1841 1847
43. J.Y. Chiang Bile acid regulation of gene expression: roles of nuclear hormone receptors Endocr. Rev. 23 2002 443 463
44. M.C. Hunt The peroxisome proliferator-activated receptor α (PPARα) regulates bile acid biosynthesis J. Biol. Chem. 275 2000 28947 28953
45. S.M. Post Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-α-mediated downregulation of cholesterol 7α-hydroxylase and sterol 27-hydroxylase expression Arterioscler. Thromb. Vasc. Biol. 21 2001 1840 1845
46. P. Zimniak Detoxification of lithocholic acid. Elucidation of the pathways of oxidative metabolism in rat liver microsomes J. Lipid Res. 30 1989 907 918
47. J.J. Repa, and D.J. Mangelsdorf The role of orphan nuclear receptors in the regulation of cholesterol homeostasis Annu. Rev. Cell Dev. Biol. 16 2000 459 481
48. K. Solaas Differential regulation of cytosolic and peroxisomal bile acid amidation in mouse liver: PPARα activation favors formation of unconjugated bile acids J. Lipid Res. 45 2004 1051 1060
49. D.A. Vessey The role of conjugation reactions in enhancing biliary secretion of bile acids Biochem. J. 214 1983 923 927
50. K. Solaas Subcellular organization of bile acid amidation in human liver: a key issue in regulating the biosynthesis of bile salts J. Lipid Res. 41 2000 1154 1162
51. M. Marrapodi, and J.Y. Chiang Peroxisome proliferator-activated receptor α (PPARα) and agonist inhibit cholesterol 7α-hydroxylase gene (CYP7A1) transcription J. Lipid Res. 41 2000 514 520
52. O. Barbier PPARα induces hepatic expression of the human bile acid glucuronidating UGT2B4 enzyme J. Biol. Chem. 278 2003 32852 32860
53. H.U. Marschall Bile acid N-acetylglucosaminidation. In vivo and in vitro evidence for a selective conjugation reaction of 7 β-hydroxylated bile acids in humans J. Clin. Invest. 89 1992 1981 1987
54. G.L. Guo Complementary roles of farnesoid X receptor, pregnane X receptor, and constitutive androstane receptor in protection against bile acid toxicity J. Biol. Chem. 278 2003 45062 45071
55. C. Viollon-Abadie Effects of model inducers on thyroxine UDP-glucuronosyl-transferase activity in vitro in rat and mouse hepatocyte cultures Toxicol. In Vitro 14 2000 505 512
56. J. Mounie Inductive effects of fenofibrate and metabolism of phenobarbital Fundam. Clin. Pharmacol. 2 1988 259 265
57. S.L. Ripp Regulation of CYP2C11 by dehydroepiandrosterone and peroxisome proliferators: identification of the negative regulatory region of the gene Mol. Pharmacol. 64 2003 113 122
58. C. Michel Liver gene expression profiles of rats treated with clofibric Acid: comparison of whole liver and laser capture microdissected liver Am. J. Pathol. 163 2003 2191 2199
59. L.Q. Fan Opposing mechanisms of NADPH-cytochrome P450 oxidoreductase regulation by peroxisome proliferators Biochem. Pharmacol. 65 2003 949 959
60. T. Kok Peroxisome proliferator-activated receptor α (PPARα)-mediated regulation of Mdr2 expression and function in mice Biochem. J. 369 2003 539 547
61. L. Huang, and M. Vore Multidrug resistance p-glycoprotein 2 is essential for the biliary excretion of indocyanine green Drug Metab. Dispos. 29 2001 634 637
62. D. Williams, and J. Feely Pharmacokinetic-pharmacodynamic drug interactions with HMG-CoA reductase inhibitors Clin. Pharmacokinet. 41 2002 343 370
63. G. Schmitz, and W. Drobnik Pharmacogenomics and pharmacogenetics of cholesterol-lowering therapy Clin. Chem. Lab. Med. 41 2003 581 589
64. A.P. Lea, and D. McTavish Atorvastatin. A review of its pharmacology and therapeutic potential in the management of hyperlipidaemias Drugs 53 1997 828 847
65. D.J. Maron Current perspectives on statins Circulation 101 2000 207 213
66. P.D. Thompson Statin-associated myopathy J. Am. Med. Assoc. 289 2003 1681 1690
67. J.A. Tobert Lovastatin and beyond: the history of the HMG-CoA reductase inhibitors Nat. Rev. Drug Discov. 2 2003 517 526
68. R. Paoletti Pharmacological interactions of statins Atheroscler. Suppl. 3 2002 35 40
69. J.T. Backman Gemfibrozil greatly increases plasma concentrations of cerivastatin Clin. Pharmacol. Ther. 72 2002 685 691
70. C. Kyrklund Plasma concentrations of active lovastatin acid are markedly increased by gemfibrozil but not by bezafibrate Clin. Pharmacol. Ther. 69 2001 340 345
71. A. Corsini The safety of HMG-CoA reductase inhibitors in special populations at high cardiovascular risk Cardiovasc. Drugs Ther. 17 2003 265 285
72. M.H. Davidson Controversy surrounding the safety of cerivastatin Expert Opin. Drug. Saf. 1 2002 207 212
73. A.B. Mulder Association of polymorphism in the cytochrome CYP2D6 and the efficacy and tolerability of simvastatin Clin. Pharmacol. Ther. 70 2001 546 551
74. D.M. Roden, and A.L. George Jr The genetic basis of variability in drug responses Nat. Rev. Drug Discov. 1 2002 37 44